Although gene therapy has been suggested to be a novel strategy to treat hepatocellular carcinoma ( HCC ) , no study showing the clinical feasibility of vectors to treat HCC has been reported. In this preclinical study, we show evidence indicating that hemagglutinating virus of Japan ( HVJ ) liposomes are a feasible vector to treat HCC in a clinical setting using ganciclovir ( GCV ) and herpes simplex virus thymidine kinase ( HSV -tk ) , which is driven by the cytomegalovirus immediate early enhancer / promoter ( plasmid pcDNA3 / HSV -tk ) . In in vitro experiments, almost complete tumor cell regression was achieved with the optimal GCV concentration ( 100 g / mL ) and more than 1 / 3 regression was seen even with a 20% transduction ratio using HuH7 HCC cells stably transformed by HSV -tk. HVJ liposomes showed a 19.7% ( mean ) transduction rate of the lacZ gene in a relatively large mass of more than 300 mm 3 in vivo, which is a clinically detectable size, implanted into SCID mice. Moreover, a single HSV -tk injection of HVJ liposomes followed by GCV treatment inhibited tumor growth at least within a week, and repeat administration was more effective. Furthermore, subcutaneous injection of an HVJ liposomes vehicle induced no apparent inflammatory response in C3H / HeN mice, whereas lacZ gene transfection resulted in inflammatory pathology, suggesting a lower immunogenicity of the HVJ envelope protein than those of bacteria -derived plasmid DNA or the -galactosidase gene product. From these findings, we conclude that HVJ liposomes are a clinically safe and effective gene transfer vector to treat HCC. Cancer Gene Therapy ( 2001 ) 8, 252 ± 258
M alignant liver neoplasms, including hepatocellular carcinoma ( HCC ) , are a main cause of death among patients with cancer especially in Japan. Because of recent advances in surgery, HCC has shown improved prognosis. 1, 2 However, the efficacy of this invasive treatment is limited because almost all patients with HCC also suffer from serious liver dysfunction due to hepatitis and cirrhosis. Several less invasive approaches, such as lipidolization, transarterial embolization, or percutaneous ethanol injection therapy, have been used also to treat HCC, but the therapeutic efficacies of these are also limited. 1 Therefore, a new therapeutic strategy is still awaited.
Gene therapy seems to be a hopeful strategy to treat HCC. Recent studies using adenovirus 3 or retrovirus 4, 5 vectors have shown some extent of the efficacy of this novel therapy. However, when considering the preclinical usefulness of gene therapy for HCC, these animal experiments seem not to be practical for clinical use. First, the tumor size is too small to be detected by clinical ultrasonography or computed tomography. Second, even if a suicide gene is used, such as the herpes simplex thymidine kinase ( HSV-tk ) gene that is expected to have a bystander effect, at least more than 10± 20% of the gene transduction rate is necessary to reduce the tumor mass volume. 6, 7 Achieving such a level of gene transfer efficiency by in vivo direct injection is relatively difficult for a retrovirus vector. Third, HCC may frequently recur in cirrhotic liver, and thus, repeated injections are necessary to treat HCC. 1, 2 An adenovirus vector can achieve a high transduction rate of therapeutic genes, but the gene transfection efficiency by repeated administration of this vector is likely to be reduced by an antiadenovirus antibody. 8 We therefore chose liposomes of the hemagglutinating virus of Japan ( HVJ ) , a viral /nonviral hybrid vector, 9 as a gene transfer vector of HCC because this system has shown a relatively low immunogenicity 10 and repeated gene transfection to liver without reduction of gene transfer efficiency in vivo. 11 These characteristics of HVJ liposomes suggest the feasibility of its clinical application for HCC.
We designed this study to clarify the clinical feasibility of HVJ liposomes for HCC using the HSV-tk gene. We used relatively large masses of more than 300 mm 3 , a clinically detectable size, by implanting human HCC cells in SCID mice. Second, we evaluated the antitumor effect of HSV-tk with ganciclovir (GCV ) administration by single or repetitive gene transfection using this vector. Third, we checked the effect of HVJ liposome administration on the body weight of immunocompetent mice and on the local inflammatory response by histopathological examination. We also discuss in this paper the advantages and possible problems of this vector system to treat patients suffering from HCC.
MATERIALS AND METHODS

Materials
Phosphatidylserine, phosphatidylcholine, and cholesterol were purchased from Sigma (St. Louis, MO ) . pCMV ( Clontech, Palo Alto, CA ) were used as reporter genes to determine in vivo gene transfer efficiency. The pcDNA3 / HSV-tk was constructed as follows. A whole coding region of HSV-tk ( 1.3 kbp ) was digested in HindIII ± ClaI from pGEM -tk ( gift from Dr. Ido, 12 the Department of Second Internal Medicine, Miyazaki Medical University ). This fragment was subcloned into the multicloning site of pcDNA3 (Invitrogen, San Diego, CA ) to be driven by a cytomegalovirus promoter /enhancer. Male SCID mice ( Nihon Clea, Tokyo, Japan ) , 6± 7 years old, were used for the in vivo gene transfer study, and C3H /HeN mice of the same age were used for the study of the safety of the HVJ liposomes. For the animal experiments in this study, we followed The Law (no. 105) and Notification (no. 6 ) of the Government and the Principles of Laboratory Animals ( publication no. NIH 80-23, revised 1985 ).
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Liposome preparation
The HVJ liposomes were prepared as described previously. 15 ± 18 Briefly, 10 mg of mixed lipids ( phosphatidylserine:phosphatidylcholine:cholesterol: = 1:4.8:2 ) was dried by reversed phase evaporation and was propagated with a DNA ( 200 g ) high mobility group 1 (64 g) complex in a balanced salt saline ( 140 mmol /L NaCl, 5.4 mmol /L KCl, 10 mmol /L Tris ±HCl, pH 7.6) solution. The solution was vortexed at 8Â30 s and multilamellar liposomes were formed. Then, 15,000 hemagglutinating activity units of purified HVJ ( Z strain ) were added to the solution followed by incubation at 378C for 1 hour. Free HVJ was removed from the HVJ liposomes by sucrose density gradient centrifugation. The top layer of the sucrose gradient containing the HVJ liposome complex was collected for use. This HVJ liposome solution was used for gene transfer by adding CaCl 2 ( final concentration 2 mmol ).
Cell line and animal model
The cell line HuH7 ( human HCC cell line ) was purchased from the Health Science Research Resources Bank (Osaka, Japan ) ( JCRB0403) . 19 ± 21 Male SCID mice, 6± 7 years old, were given subcutaneous (s.c. ) injections of 5Â10 6 HuH7 cells in the bilateral back.
In vitro optimization of GCV concentration
To establish stably transformed HuH7 cells with HSV-tk, the cells were first transfected with pcDNA3 /HSV-tk using lipofectAMINE Reagent (Gibco BRL, Gaitherburg, MD ) . The cells were then cultured in the medium with fetal bovine serum containing 0.5 mg / mL G418 ( Gibco BRL ) for 2 weeks, and stable transformant cells with the HSV-tk gene were selected. Exponentially growing stable transformant cells were seeded onto six -well culture dishes at a concentration of 1Â10 5 cells in each well. The next day, various concentrations of GCV were added. One and three days after adding GCV, the viable cell numbers were stained with 0.3% Trypan blue and were counted using a hemocytometer.
Evaluation of in vitro bystander effect
Parental HuH7 cells were mixed and cocultured with HSVtk stably expressing HuH7 cells at various ratios, and were seeded at a density of 1Â10 5 cells in each well at a subconfluent condition. Four days after coculturing with 100 g /mL GCV, the viable cell numbers were stained with 0.3% Trypan blue and were counted using a hemocytometer. The survival ratio was calculated by comparing the live cells cultured with and without transduced cells.
Evaluation of in vivo gene transfer efficiency using the lacZ gene
The transduction efficiency of HVJ liposomes into in vivo tumors was tested using the reporter gene pCMV. Approximately 3 weeks after s.c. injecting HuH7 cells of more than 300 mm 3 , 500 L of HVJ liposomes solution containing 25 g of pCMV, 1.25 mg lipids, and 1875 hemagglutinating activity units of HVJ was injected into the tumor. Five days after gene infection, the mouse was killed and the tumor was fixed with ice -cooled 1% glutaraldehyde for 20 minutes. The lacZ gene ±infected tumor was divided into three parts, was embedded in OCT compound ( Sakura Finetechnical, Tokyo, Japan ) , and was cut into 5 -m ±thick cryostat sections for X -gal histochemistry or hematoxylin ± eosin staining. The tissue sections were placed in X -gal solution (5 mM potassium ferrous cyanide, 5 mM ferric cyanide, 2 mM magnesium chloride, 1 mg /mL 5 -bromo-4 -chloro -3 -indolyl --D -galactopyranoside ) for 12 hours at room temperature. Tumor sections were traced under a light microscope and the signal intensities and the numbers of Xgal ±positive cells were counted at three random fields of one section. The transfection efficiency is shown as the proportion of lacZ -positive cell number SD (lacZ, n =3; control, n =3).
Tumor treatment protocols
About 3 weeks after implanting of the HuH7 cells, 500 L of HVJ liposome solution with pcDNA3 /HSV-tk was directly injected into one side of the mice and 500 L of HVJ liposomes without DNA was directly administered into the other side of the mice along two different routes using a 30 -gauge needle. The needle was withdrawn after 10 seconds. The following day, GCV was administered intraperitoneally ( i.p. ) at 25 mg /kg once daily for 7 days (Fig 1A ) . Figure  1B tumor volume was calculated as: width 2 ÂlengthÂ0.5, 22 and the tumor volume ratio was calculated as the ratio to the 0 day tumor volume at day 0.
Evaluation of the safety of HVJ liposome
To evaluate the effect of HVJ liposomes, 500 -L solutions were injected s.c. once a week into the back of C3H /HeN mice using a 30 -gauge needle for 2 weeks. The mice were divided into three groups, and each group was injected with either saline (n =3 ), HVJ liposomes without DNA ( n=3), and HVJ liposomes with lacZ plasmids ( n= 3) . The body weights of the mice were measured twice a week. A week after the last injections, the mice were killed and their skin samples were dissected. Sections of their skin samples were fixed in 10% formaldehyde, were embedded in paraffin, and 5-m ± thick sections were stained with ordinary hematoxylin ± eosin for light microscopic examination.
Statistical analysis
All values were expressed at the mean SD. Statistical evaluations of the differences in the two groups were made using the Mann -Whitney U test. A P value of <.05 was considered significant.
RESULTS
In vitro evaluation of bystander effect
We optimized the GCV concentration to stably transform HuH7 cells using pcDNA3/ HSV-tk. Control cells were not tranfected and were grown as stable transformant cells. The cell number of untransfected HuH7 control cells with 100 g /mL GCV and transformant cells without GCV treatment increased gradually (three times the cell number for 6 days ) , whereas the number of stable transformant cells with GCV treatment decreased in dose -dependent manner (half the cell number for 6 days with 10 g/ mL GCV ) .
Next, we tried to evaluate the bystander effect on HuH7 cells using HSV-tk stably transformant cells. When HuH7 cells transformed by pcDNA3/ HSV-tk were mixed at proportions 10%, 20%, 50%, and 75%, the relative survival rates of the parental cells were 43.0 12.3%, 32.5 2.1%, 17.8 1.1%, and 11.8 5.7%, respectively.
In vivo transfection efficiency
In tumors injected with HVJ liposomes without plasmid DNA, no blue -stained cells were observed, whereas disseminated X -gal ± positive cells were recognized in the tumor sections transfected with pCMV. The proportion of X -gal ± positive cells was 19.7 6.0% of the section ( Fig 2 ) .
Single or repeated administration of HSV -tk and GCV
Three weeks after inoculating the tumor cells into the back of SCID mice, the tumor size increased to 300± 500 mm 3 in volume. The size of tumors treated with HSV-tk and GCV was apparently unchanged, but tumors treated with the HVJ liposome vehicle increased gradually (Fig 3 ) . Significant differences were observed between these two groups at 3, 5, and 7 days (P < .05) . However, more than 7 days after the HVJ liposome/ HSV-tk complex injections, the tumor sizes gradually increased.
To evaluate the effectiveness of repeat administrations of pcDNA3/ HSV-tk by HVJ liposomes and GCV, the treatments were made twice ( Fig 1B ) . Here, we used antitumor drugs for 5 days because in our pilot study, some mice were lost by 10 days of daily administration of GCV, probably due to adverse effects of GCV such as bone marrow suppression ( data not shown ). More than 7 days later, the tumors treated once with HSV-tk gradually increased to several times the initial size, whereas tumors treated twice increased up to twice the initial size after 7 days (Fig 4 ) , indicating the effective repeated administration of HSV-tk treatment by HVJ liposomes.
The safety of HVJ liposomes
Although the fact Ð that native HVJ infection is pathogenic for rodents, resulting in pneumonia and cytokine production Ð is well recognized, no report exists, indicating that these effects may be induced by HVJ envelope proteins or by HVJ nucleocapsid proteins. Thus, we checked the inflammatory reaction and the related adverse effect by injecting HVJ liposomes into the skin of mice. In this study, we used HVJ liposome vehicles and HVJ liposomes containing pCMV to assess the inflammatory property of HVJ envelope proteins and we compared this property directly with bacteriaderived plasmid DNA expressing the bacterial gene (lacZ ), both of which stimulated inflammation in vivo.
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The body weights of mice with HVJ liposome vehicle increased by the same amount as those of control mice receiving saline only (Fig 5 ) . In contrast, the body weights of mice treated with HVJ liposome / lacZ were significantly lower than those of the control or HVJ liposome vehicletreated mice (Fig 5 ) . Light microscopic examination showed no apparent inflammatory reaction in the tissue sections of saline -injected mice or mice with HVJ liposome vehicle, but showed massive s.c. fibrosis, enriched collagen bundles, chronic inflammatory infiltration, and hyperkeratosis in the mice with HVJ liposome / lacZ (Fig 6a,c,e ) . These findings suggest the immunogenicity of -galactosi- Figure 3 . Effect of HSV -tk transfection and GCV treatment on HCC tumor growth by single administration. Tumors treated with HSV -tk and GCV were almost the same size, but tumors treated with liposomes increased gradually. Significant differences were observed between these two groups at 3, 5, and 7 days ( P < .05 ) . Figure 4 . Effect of repeat therapy using HSV -tk and GCV. More than 7 days later, one treatment gradually increased the tumors to several times the initial size, but two treatments increased the tumor size up to twice the initial size. All mice treated with a single injection survived 14 days, whereas mice treated twice survived for more than 18 days. HASEGAWA, SHIMADA, YONEMITSU, ET AL: HVJ LIPOSOMES AS GENE TRANSFER VECTOR dase gene products or plasmid DNA itself, and that HVJ liposome seems a less inflammatory agent compared with them.
DISCUSSION
Several experimental gene therapies for malignant neoplasms have been reported using various vectors with suicide genes 3 ± 5 or cytokine genes. 26 ± 28 However, each vector has certain problems for clinical application, such as toxicity or immunogenicity of the adenoviral vector 8 and the cancerogenic potential of the retroviral vector. 29 HVJ liposomes have some advantages compared with other viral vectors: ( a) no requirement of cell proliferation; ( b) no limitation of insert size of exogenous genes; and ( c) no apparent toxicity. 10 These characteristics suggest a clinical feasibility of HVJ liposomes.
In this study, a clinically detectable size of tumors in the liver was evaluated. In other studies for cancer gene therapy, relatively small tumors, such as 100 ±200 mm 3 in volume, 30, 31 were used, which seem clinically difficult to detect. In clinical studies, initial noninvasive screening using computed tomography and ultrasonography can detect tumors of more than 5 mm in diameter, which is comparable to 300 mm 3 . Therefore, we selected a tumor volume of approximately 300 ± 500 mm 3 in this study, which was clinically suitable for the experimental conditions in this study. According to this study, the gene transfer efficiency of HVJ liposome into the murine HCC tumor was approximately 20% of the whole tumor. In our in vitro study using a stable transformant, 20% of cells expressing HSV-tk led to 70% cell deaths of the total cell number (data not shown) . A tumor mass regresses because of the bystander effect, when about 10 ±20% of HSV-tk ± transferred cells of the whole tumor is present. 6, 7, 32 These data are similar to the findings of this study, from which we suggest that HVJ liposomes are appropriate for HCC gene therapy using HSV-tk. We used a HVJ liposome vehicle in this growth inhibition study because bacteria -derived plasmid DNA can induce host inflammatory reaction, and we consider this to affect the growth of the tumor.
With a single administration of HSV-tk, the tumor growth was inhibited, but it was difficult for the tumors to regress. These findings suggest an antitumor effect of HSV-tk, but the effect was limited to 7 days. We suggest that the relatively short doubling time of HuH7 might overcome the antitumor effect of HSV-tk with GCV, or that the transfection efficiency might not be sufficient to reduce the tumor size because the tumor sizes were too large. We tried, therefore, repeated injections of HVJ liposome/ HSV-tk because effective results of repeated injections were reported by Yonemitsu et al. 9 Tumor growths with two injections of HVJ liposome /HSV-tk were suppressed, indicating that repeated injections of HVJ liposome /HSV-tk seem to be more effective for HuH7 tumors than single administrations, but the tumors did not regress in this study. According to our pilot study, we found that almost all SCID mice were unhealthy with only a daily injection of GCV at a dose of 25 mg / kg, and some of them were dead at around 10 days or later. Histological examination showed suppressed bone marrow, suggesting the adverse effect of GCV. Therefore, we here used the``5 days daily injection and 2 days interval'' protocol in a repeated administration experiment. After all, we feel that more initial experiments to optimize the effective dose or timing of gene transfection are required in the near future to regress such relatively large tumor masses.
To study the safety of HVJ liposome, we used C3H / HeN mice because they have a normal immune system and HVJ is pathogenic for rodents. Cytotoxic T lymphocytes have an important and central role in the cellular immune response to acute viral infection and in the elimination of viruses and gene -transferred cells. HVJ liposomes contain several viral components, such as HN and F envelope protein, that are possibly exposed to the cellular immune system. 11, 33 In our study, body weights were measured and histopathological studies were made; the body weights of saline -injected control mice and HVJ liposome vehicle-injected mice showed no significant differences, and no lymphocytic infiltration and inflammatory reaction was observed in the histopathological study. These results suggest a low immunogenicity of HVJ liposomes, which is probably due to the destruction of the viral genome using ultraviolet irradiation during preparation. However, an apparent inflammatory and healing reaction was recognized in the mice skin injected with HVJ liposomes with the lacZ gene. These findings suggest the antigenicity of the -galactosidase protein; similar findings were reported from other studies, 34 and important studies of toxicity or inflammation induced by bacteria -derived plasmid DNA in vivo have been made. 26, 27 In this study, one aim was to address the adverse effect of the HVJ liposome vehicle, but not plasmid DNA or the -galactosidase gene product. 28 Therefore, in this study, the control was HVJ liposomes with the lacZ gene, and the noncoding``empty'' plasmid DNA was not needed as the control.
CONCLUSION
We here report evidence of the preclinical feasibility of HVJ liposomes as a gene transfer vector to treat HCC. We believe that gene therapy for HCC using HVJ liposome /HSV-tk can be applied clinically.
